http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 08 May 2026 16:46:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Mar+31/26462054.html si-local-file:///var/storage/secattach/20260508/26462054.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Mar+31/26462054.html Fri, 08 May 2026 16:46:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Mar+31/26462054.html si-local-file:///var/storage/secattach/20260508/26462054.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Mar+31/26462054.html Fri, 08 May 2026 16:46:00 -0400 CELZ O.07026615 http://www.streetinsider.com/Corporate+News/Creative+Medical+reports+93%25+response+rate+in+knee+osteoarthritis+study/26379630.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) reported that 93% of patients in a pilot study of its Ultrasome knee osteoarthritis treatment showed clinically meaningful improvements in mobility and pain reduction. The company said the therapy was well-tolerated with no serious adverse events reported.</p><p>Ultrasome is derived from Creative Medical's CELZ-201 cell therapy product, which is currently being evaluated in an FDA-cleared clinical trial called ADAPT. The cell-free format is designed to enable scalable manufacturing, reduced production costs, and off-the-shelf availability compared to traditional cell therapies.</p><p>The biotechnology company said osteoarthritis affects over 30 million adults in the United States. Current treatments http://www.streetinsider.com/Corporate+News/Creative+Medical+reports+93%25+response+rate+in+knee+osteoarthritis+study/26379630.html Tue, 28 Apr 2026 09:02:02 -0400 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html <p align="center"><em>Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced </em><em>CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market</em></p> <p align="justify">PHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ)</strong>, a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced breakthrough positive results from its pilot study of Ultrasome™, the Company’s proprietary cell-free regenerative therapy for the treatment of osteoarthritis (OA) of the knee.</p> <p align="justify">The study achieved its primary endpoint with an industry-leading 93% of patients demonstrating clinically meaningful improvements in mobility and pain reduction, with the therapy well-tolerated and no serious adverse http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings%2C+Inc.+Reports+Breakthrough+93%25+Response+Rate+in+Ultrasome%E2%84%A2+Knee+Osteoarthritis+Program%2C+Expanding+CELZ-201+Platform+into+Scalable+Cell-Free+Regenerative+Therapie/26379598.html Tue, 28 Apr 2026 09:01:00 -0400 A.18970468 A.50203557 CELZ O.00050857 O.07026615 O.36684209 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26366917.html si-local-file:///var/storage/secattach/20260424/26366917.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26366917.html Fri, 24 Apr 2026 16:45:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26366917.html si-local-file:///var/storage/secattach/20260424/26366917.html http://www.streetinsider.com/SEC+Filings/Form++10-KA+++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26366917.html Fri, 24 Apr 2026 16:45:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26198288.html si-local-file:///var/storage/secattach/20260320/26198288.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26198288.html Fri, 20 Mar 2026 16:46:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26198288.html si-local-file:///var/storage/secattach/20260320/26198288.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Dec+31/26198288.html Fri, 20 Mar 2026 16:46:00 -0400 CELZ O.07026615 http://www.streetinsider.com/Corporate+News/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced that the World Health Organization has published the proposed International Nonproprietary Name "etaroleucel" for CELZ-101, the company's autologous regulatory T-cell immunotherapy program.</p><p>The WHO published the proposed name in Proposed INN List 134 following expert review during the 80th WHO INN Consultation held March 18-21, 2025. The name is now entering the formal objection period before final confirmation under standard WHO procedures.</p><p>CELZ-101 is designed to induce immune tolerance in autoimmune settings, including Type 1 diabetes in pancreatic islet transplantation contexts. The platform has been validated in cardiovascular and hepatic clinical applications, according to http://www.streetinsider.com/Corporate+News/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html Tue, 10 Feb 2026 09:00:44 -0400 CELZ http://www.streetinsider.com/FDA/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html <p>Creative Medical Technology Holdings Inc. (NASDAQ: CELZ) announced that the World Health Organization has published the proposed International Nonproprietary Name "etaroleucel" for CELZ-101, the company's autologous regulatory T-cell immunotherapy program.</p><p>The WHO published the proposed name in Proposed INN List 134 following expert review during the 80th WHO INN Consultation held March 18-21, 2025. The name is now entering the formal objection period before final confirmation under standard WHO procedures.</p><p>CELZ-101 is designed to induce immune tolerance in autoimmune settings, including Type 1 diabetes in pancreatic islet transplantation contexts. The platform has been validated in cardiovascular and hepatic clinical applications, according to http://www.streetinsider.com/FDA/Creative+Medical+receives+second+WHO+name+designation+for+cell+therapy/25972330.html Tue, 10 Feb 2026 09:00:44 -0400 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0400 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0400 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0400 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html <p align="justify">PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) milestone with the World Health Organization (WHO), marking continued regulatory progress across its expanding clinical pipeline. INNs are assigned by the WHO to uniquely and universally identify pharmaceutical substances and biologics worldwide.</p> <p align="justify">The WHO has published the proposed INN “etaroleucel” for CELZ-101, the Company’s autologous regulatory T-cell (Treg) immunotherapy program, in Proposed INN List http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Achieves+Second+WHO+INN+Milestone%2C+Strengthening+Global+Regulatory+Positioning+Across+Expanding+Cell+Therapy+Pipeline/25972269.html Tue, 10 Feb 2026 09:00:00 -0400 A.17568957 A.18970468 A.50203557 CELZ O.00050857 O.04889877 O.07026615 O.36684209